CVT's Cold-FX Approved by Health Canada for Colds.

Business Editors

EDMONTON, Alberta--(BUSINESS WIRE)--April 11, 2000

(CDNX:CVQ.)

Health Canada has accepted CV Technologies' proprietary product Cold-FX(R) to be used for "Relief of Coughs due to Colds" after a rigorous natural health product review. Cold-FX(R) is a powerful stimulant to the body's natural immune system and was developed utilizing the Company's proprietary ChemBioPrint(TM) standardization and certification technology. As previously disclosed, DuPont Consumer Health has been working with CV Technologies Inc. to analyze CVT's ChemBioPrint(TM) technology in recent months.

Health Canada, in the course of their investigation, has recognized CV Technologies' ability to assure consistent quality by allowing the statement "Batch-to-Batch Quality Guaranteed by Consistent Chemical and Biological Profile" to appear on the Cold-FX(R) package.

"The Health Canada labeling approval for Cold-FX(R), which is the first of its kind, coupled with DuPont's involvement in the ChemBioPrint(TM) technology shows the leading-edge position CV Technologies has established in the natural health products industry," said Jim Bruce, CV Technologies' President and CEO. The allowed claim and the recognition of batch-to-batch quality by a national health-regulatory authority substantiate the validity of the Company's ChemBioPrint(TM) technology.

Cold-FX(R) is a proprietary ginseng extract that has been sold as an immune-enhancing product in the natural health products market. The new labeling will permit more directed and aggressive promotion of the product to the consumer in the much larger, over-the-counter (OTC) cold and flu remedy market. Cold-FX(R) is differentiated from other natural products because its specific therapeutic claim has been approved by a national agency.

Cold-FX(R) has been issued the Drug Identification Number (DIN) 02242024. According to Health Canada, the DIN is assigned "to each drug approved for use in Canada in accordance with the Food and Drug Regulations." (Health Canada is the department of the Canadian government responsible for drug regulation.)

About CV Technologies

CV Technologies (CVT) is an international science and technology company which has developed and commercialized proprietary technology to identify, extract, and biologically standardize natural mixtures which deliver health benefits. CVT's research facilities are located in Edmonton, Alberta. CVT has a staff of 40 people including 14 with Ph.D.s and 2 M.D.s. The Company maintains two full-scale laboratories and has access to 18 satellite facilities including offices in Boulder, Colorado and Hong Kong.

Utilizing the Company's ChemBioPrint(TM) technology, CVT scientists obtain specific chemical and biological profiles of natural mixtures, in addition to determining their mechanisms of action and optimal dosages. The result is the development of precise operating procedures for commercial production. All CVT products are certified effective, safe, biologically active, and consistent, batch-to-batch.

CV Technologies markets products in Canada under its HerbTech(R) brand name and supplies proprietary ingredients to national and international markets. The Company currently holds 18 patents, which includes 10 U.S. patents. An additional 29 patents are pending, worldwide. Two Patent Cooperation Treaty applications have been filed.

James H. Bruce, President and Chief Executive Officer CV Technologies Inc.

Canadian Venture Exchange trading symbol: CVQ

"The Canadian Venture Exchange has neither approved nor disapproved the information contained herein."

CV Technologies Inc., Suite 308, 8625 - 112 Street, Edmonton, Alberta CANADA T6G 1K8